Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1998 1
2006 2
2007 2
2008 1
2009 2
2010 1
2011 3
2012 5
2013 5
2014 3
2015 1
2016 2
2017 3
2019 5
2020 5
2021 5
2022 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.
Bialucha CU, Collins SD, Li X, Saxena P, Zhang X, Dürr C, Lafont B, Prieur P, Shim Y, Mosher R, Lee D, Ostrom L, Hu T, Bilic S, Rajlic IL, Capka V, Jiang W, Wagner JP, Elliott G, Veloso A, Piel JC, Flaherty MM, Mansfield KG, Meseck EK, Rubic-Schneider T, London AS, Tschantz WR, Kurz M, Nguyen D, Bourret A, Meyer MJ, Faris JE, Janatpour MJ, Chan VW, Yoder NC, Catcott KC, McShea MA, Sun X, Gao H, Williams J, Hofmann F, Engelman JA, Ettenberg SA, Sellers WR, Lees E. Bialucha CU, et al. Among authors: bilic s. Cancer Discov. 2017 Sep;7(9):1030-1045. doi: 10.1158/2159-8290.CD-16-1414. Epub 2017 May 19. Cancer Discov. 2017. PMID: 28526733
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Crawford TO, Darras BT, Day JW, Dunaway Young S, Duong T, Nelson LL, Barrett D, Song G, Bilic S, Cote S, Sadanowicz M, Iarrobino R, Xu TJ, O'Neil J, Rossello J, Place A, Kertesz N, Nomikos G, Chyung Y. Crawford TO, et al. Among authors: bilic s. Neurology. 2024 Mar 12;102(5):e209151. doi: 10.1212/WNL.0000000000209151. Epub 2024 Feb 8. Neurology. 2024. PMID: 38330285 Clinical Trial.
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G, Xia D, So PP, Hilton SK, Evandy C, Sarkar S, Martin U, Krostag AR, Leonardi M, Zak DE, Logan R, Lewis P, Franke-Welch S, Ngwenyama N, Fitzgerald M, Tulberg N, Rawlings-Rhea S, Gardner RA, Jones K, Sanabria A, Crago W, Timmer J, Hollands A, Eckelman B, Bilic S, Woodworth J, Lamble A, Gregory PD, Jarjour J, Pogson M, Gustafson JA, Astrakhan A, Jensen MC. Appelbaum J, et al. Among authors: bilic s. J Clin Invest. 2024 Mar 19:e162593. doi: 10.1172/JCI162593. Online ahead of print. J Clin Invest. 2024. PMID: 38502193 Free article.
Structure of Dark Triad Dirty Dozen Across Eight World Regions.
Rogoza R, Żemojtel-Piotrowska M, Jonason PK, Piotrowski J, Campbell KW, Gebauer JE, Maltby J, Sedikides C, Adamovic M, Adams BG, Ang RP, Ardi R, Atitsogbe KA, Baltatescu S, Bilić S, Bodroža B, Gruneau Brulin J, Bundhoo Poonoosamy HY, Chaleeraktrakoon T, Del Carmen Dominguez A, Dragova-Koleva S, El-Astal S, Eldesoki WLM, Gouveia VV, Gundolf K, Ilisko D, Jukić T, Kamble SV, Khachatryan N, Klicperova-Baker M, Kovacs M, Kozytska I, Larzabal Fernandez A, Lehmann K, Lei X, Liik K, McCain J, Milfont TL, Nehrlich A, Osin E, Özsoy E, Park J, Ramos-Diaz J, Riđić O, Qadir A, Samekin A, Tiliouine H, Tomsik R, Umeh CS, van den Bos K, Van Hiel A, Vauclair CM, Włodarczyk A. Rogoza R, et al. Among authors: bilic s. Assessment. 2021 Jun;28(4):1125-1135. doi: 10.1177/1073191120922611. Epub 2020 Jun 2. Assessment. 2021. PMID: 32484407
Country-level correlates of the Dark Triad traits in 49 countries.
Jonason PK, Żemojtel-Piotrowska M, Piotrowski J, Sedikides C, Campbell WK, Gebauer JE, Maltby J, Adamovic M, Adams BG, Kadiyono AL, Atitsogbe KA, Bundhoo HY, Bălțătescu S, Bilić S, Brulin JG, Chobthamkit P, Del Carmen Dominguez A, Dragova-Koleva S, El-Astal S, Esteves CS, Labib M Eldesoki W, Gouveia VV, Gundolf K, Ilisko D, Jauk E, Kamble SV, Khachatryan N, Klicperova-Baker M, Knezovic E, Kovacs M, Lei X, Liik K, Mamuti A, Moreta-Herrera CR, Milfont TL, Wei Ong C, Osin E, Park J, Petrovic B, Ramos-Diaz J, Ridic G, Qadir A, Samekin A, Sawicki A, Tiliouine H, Tomsik R, Umeh CS, van den Bos K, Van Hiel A, Uslu O, Wlodarczyk A, Yahiiaev I. Jonason PK, et al. Among authors: bilic s. J Pers. 2020 Dec;88(6):1252-1267. doi: 10.1111/jopy.12569. Epub 2020 Jul 1. J Pers. 2020. PMID: 32557617
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Cohen PA, Webb PM, King M, Obermair A, Gebski V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileshkin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Cohen PA, et al. Among authors: bilic s. Int J Gynecol Cancer. 2022 Apr 4;32(4):560-565. doi: 10.1136/ijgc-2021-002999. Int J Gynecol Cancer. 2022. PMID: 34551895 Clinical Trial.
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.
Denisenko E, de Kock L, Tan A, Beasley AB, Beilin M, Jones ME, Hou R, Muirí DÓ, Bilic S, Mohan GRKA, Salfinger S, Fox S, Hmon KPW, Yeow Y, Kim Y, John R, Gilderman TS, Killingbeck E, Gray ES, Cohen PA, Yu Y, Forrest ARR. Denisenko E, et al. Among authors: bilic s. Nat Commun. 2024 Apr 3;15(1):2860. doi: 10.1038/s41467-024-47271-y. Nat Commun. 2024. PMID: 38570491 Free PMC article.
46 results